NICE technology appraisal guidance
Issued: January 2002
TA32
Beta interferon and glatiramer acetate for the treatment of multiple sclerosis
This is an extract from the guidance and may be misleading if read alone. The complete guidance is available at guidance.nice.org.uk/ta32
Important information about this guidance
The planned review date for this guidance was November 2004. In December 2004, NICE proposed that the review be deferred until November 2006, pending data from the Department of Health risk sharing scheme. Following consultation, NICE has decided to proceed with this proposal.